Current Concepts in the Management of Relapsed/Refractory Multiple Myeloma: Considerations With Bispecific Anti-BCMA Antibodies
Podcast 2: Multiple Myeloma in the Community Setting: Evolving Treatments for Improved Care
Post-Test/Evaluation

Questions marked with a * are required

20%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Laura is a 74-year-old woman with multiple myeloma. In the past, she has received an immunomodulatory agent, a proteasome inhibitor, and a combination therapy that incorporated an anti-CD38 antibody. She presents with another relapse. Given her triple-class resistance, what would be her prognosis at this time with regard to overall survival (before trying a 4^th-line therapy)?

A. 1-4 months

B. 6-12 months

C. 2-3 years

D. 4-5 years

In a patient who has developed resistance to at least four courses of multiple myeloma therapy, an FDA-approved agent or clinical trial of an investigational agent from which of the following classes would be most appropriate?

A. Corticosteroids

B. B cell maturation antigen (BCMA) therapies

C. Proteasome inhibitors

D. Immunomodulatory drugs